CLAIMS

1. Use of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS).
2. Use of an IFN in combination with an antiviral agent for the manufacture of a medicament useful for treatment and/or prevention of SARS for simultaneous, sequential or separate use.
3. The use according to claims 1 or 2, wherein said antiviral agent is Ribavirin.
4. The use according to any of the preceding claims, wherein said IFN is recombinant human IFN-beta.
5. The use according to any of claims 1 to 9, wherein said IFN is consensus interferon.
6. The use according to any of the preceding claims, wherein said IFN is a fused protein comprising at least an immunoglobulin domain.
7. The use according to any of the preceding claims, wherein said IFN is administered at a dosage of about 1 to 50 µg per person per day, or about 10 to 30 µg per person per day or about 10 to 20 µg per person per day.
8. The use according to any of the preceding claims, wherein said IFN is administered daily or every other day.
9. The use according to any of the preceding claims, wherein said IFN is administered twice or three times per week.
10. The use according to any of the preceding claims, wherein said IFN is administered subcutaneously.
11. The use according to any of the preceding claims, wherein said IFN is administered intramuscularly.
12. The use according to any of the preceding claims, wherein the antiviral agent is administered at a dosage of about 100 to 2000 mg per person per day, or about 400 to 1200 mg per person per day, or about 800 to 1000 mg per person per day, or about 1000 to 1200 mg per person per day.
13. The use according to any of the preceding claims, wherein Ribavirin is administered orally.